Kojic Acid for Skin Rejuvenation - Quick Reference Sheet
evipedia.ai
← Back

Kojic Acid for Skin Rejuvenation

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Kojic acid, a mold-derived cosmetic skin lightener, is applied to the face to fade dark patches and even out tone. It is a modest, well-tolerated option rather than a powerful one: stubborn sun- and hormone-driven facial darkening improves, usually alongside exfoliating acids or other lighteners, while sharply defined age spots respond poorly. Irritation is mostly mild; true allergy is less common but permanent. Benefits depend on daily sun protection. (Full Review)

Protocol

Standard concentration
1–2% cream, serum or gel
1% in EU-compliant products; trials used 0.75–2%
Best time of day
Evening, once nightly
Avoids sun on freshly treated skin; morning sunscreen completes the regimen
Course length
8–12 weeks
Initial course, then reassessment and maintenance
Time to effect
Melasma reduction
8–12 weeks
Meaningful reduction; slower than 4% hydroquinone
General facial dyschromia
12 weeks
Lightening equivalent to 4% hydroquinone with twice-daily combination use
Faint improvement
2–4 weeks
May appear before meaningful melasma reduction

Benefits

Contraindications
  • Positive patch test to kojic acid or prior allergic dermatitis from a kojic acid product
  • Active eczema, dermatitis, sunburn or broken skin at the application site (until fully healed)
  • Pregnancy and breastfeeding
  • Children under 12 years
  • Uncontrolled thyroid disease (TSH outside the reference range) when considering large-area or whole-body use
    •
Key Interactions
  • Topical retinoids (tretinoin, adapalene, tazarotene): Caution
  • Prescription hydroquinone (4%): Monitor
  • Topical corticosteroids (anti-inflammatory steroid creams: betamethasone valerate, hydrocortisone): Caution
  • Thyroid medications (levothyroxine, methimazole): Monitor (theoretical)
  • Photosensitizing drugs (doxycycline, isotretinoin, hydrochlorothiazide): Caution
  • Over-the-counter exfoliating acids (glycolic, lactic, salicylic acid): Caution
  • Over-the-counter benzoyl peroxide: Caution
  • Topical lightening supplements and cosmeceuticals, skincare products with drug-like actives (vitamin C, niacinamide, arbutin, azelaic acid, tranexamic acid): Additive (monitor)
  • Oral supplements with additive effects (Polypodium leucotomos fern extract, glutathione): Additive (monitor)
  • Procedures (chemical peels, lasers, microneedling): Caution
    •

Risk & Side Effects

  • High: Irritant skin reactions
    •
  • Medium:
  • Low: Allergic contact dermatitis
    •
  • Speculative: Thyroid disruption and thyroid tumor promotion; liver tumor promotion; genotoxicity and photo-genotoxicity
    •

Monitoring

Marker Target Why
mMASI score No fixed target; ≥50% reduction from own baseline by 12 weeks marks a good response Tracks melasma extent and darkness
Melanin index (skin reflectance meter) No established target; change from own baseline Objective pigment reading
Standardized photographs (visible and UV) Stable or lighter than baseline Visual record of response
Patch test Negative at 48–96 hours Screens for allergy
TSH 0.5–2.5 mIU/L Thyroid function screen
Free T4 1.0–1.5 ng/dL Confirms thyroid hormone output

Cadence: Baseline photographs, mMASI and patch test; tolerance at 2 and 4 weeks, efficacy at 8 and 12 weeks, then every 3–6 months during maintenance. Thyroid tests every 6–12 months only in the thyroid-risk group.

Qualitative Assessment

  • Evenness of skin tone in natural daylight
  • Amount of makeup or concealer needed
  • Frequency of stinging, itching or redness after application
  • Melasma-related quality of life, e.g., the MELASQOL questionnaire
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.